Drug intelligence / Profile preview

TA-191

Development stage: Unknown
Lead developer: TechnoPhage

Overview

TA-191 is an immunomodulator drug initially developed by TechnoPhage SA. Its mechanism of action is as an immunomodulator, and it is classified as an immunoglobulin. The drug’s highest R&D status is preclinical, and there are no approved indications or clinical trial results publicly available[1].

Beyond the preview

Go deeper on TA-191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TA-191.

Explore the full profile